Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

204 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma.
McNamara MG, Swain J, Craig Z, Sharma R, Faluyi O, Wadsley J, Morgan C, Wall LR, Chau I, Reed N, Sarker D, Margetts J, Krell D, Cave J, Sothi S, Anthoney A, Bell C, Patel A, Oughton JB, Cairns DA, Mansoor W, Lamarca A, Hubner RA, Valle JW. McNamara MG, et al. Among authors: cave j. EClinicalMedicine. 2023 Jun 2;60:102015. doi: 10.1016/j.eclinm.2023.102015. eCollection 2023 Jun. EClinicalMedicine. 2023. PMID: 37287870 Free PMC article.
Innovations in Amputation Rehabilitation and Prosthetic Design.
Matsumoto ME, Cave J 2nd, Shaffer J. Matsumoto ME, et al. Among authors: cave j 2nd. Phys Med Rehabil Clin N Am. 2024 Nov;35(4):879-896. doi: 10.1016/j.pmr.2024.06.008. Epub 2024 Jul 23. Phys Med Rehabil Clin N Am. 2024. PMID: 39389642 Review.
MHC Hammer reveals genetic and non-genetic HLA disruption in cancer evolution.
Puttick C, Jones TP, Leung MM, Galvez-Cancino F, Liu J, Varas-Godoy M, Rowan A, Pich O, Martinez-Ruiz C, Bentham R, Dijkstra KK, Black JRM, Rosenthal R, Kanu N, Litchfield K, Salgado R, Moore DA, Van Loo P, Jamal-Hanjani M, Quezada SA; TRACERx Consortium; Swanton C, McGranahan N. Puttick C, et al. Nat Genet. 2024 Oct;56(10):2121-2131. doi: 10.1038/s41588-024-01883-8. Epub 2024 Oct 2. Nat Genet. 2024. PMID: 39358601 Free PMC article.
Translational modeling-based evidence for enhanced efficacy of standard-of-care drugs in combination with anti-microRNA-155 in non-small-cell lung cancer.
Dogra P, Shinglot V, Ruiz-Ramírez J, Cave J, Butner JD, Schiavone C, Duda DG, Kaseb AO, Chung C, Koay EJ, Cristini V, Ozpolat B, Calin GA, Wang Z. Dogra P, et al. Among authors: cave j. Mol Cancer. 2024 Aug 2;23(1):156. doi: 10.1186/s12943-024-02060-5. Mol Cancer. 2024. PMID: 39095771 Free PMC article.
Author Correction: The evolution of lung cancer and impact of subclonal selection in TRACERx.
Frankell AM, Dietzen M, Al Bakir M, Lim EL, Karasaki T, Ward S, Veeriah S, Colliver E, Huebner A, Bunkum A, Hill MS, Grigoriadis K, Moore DA, Black JRM, Liu WK, Thol K, Pich O, Watkins TBK, Naceur-Lombardelli C, Cook DE, Salgado R, Wilson GA, Bailey C, Angelova M, Bentham R, Martínez-Ruiz C, Abbosh C, Nicholson AG, Le Quesne J, Biswas D, Rosenthal R, Puttick C, Hessey S, Lee C, Prymas P, Toncheva A, Smith J, Xing W, Nicod J, Price G, Kerr KM, Naidu B, Middleton G, Blyth KG, Fennell DA, Forster MD, Lee SM, Falzon M, Hewish M, Shackcloth MJ, Lim E, Benafif S, Russell P, Boleti E, Krebs MG, Lester JF, Papadatos-Pastos D, Ahmad T, Thakrar RM, Lawrence D, Navani N, Janes SM, Dive C, Blackhall FH, Summers Y, Cave J, Marafioti T, Herrero J, Quezada SA, Peggs KS, Schwarz RF, Van Loo P, Miedema DM, Birkbak NJ, Hiley CT, Hackshaw A, Zaccaria S; TRACERx Consortium; Jamal-Hanjani M, McGranahan N, Swanton C. Frankell AM, et al. Among authors: cave j. Nature. 2024 Jul;631(8022):E15. doi: 10.1038/s41586-024-07738-w. Nature. 2024. PMID: 38965439 Free PMC article. No abstract available.
204 results